Dry Age-Related Macular Degeneration Market The healthcare landscape in 2025 is poised for a transformative shift, driven by innovation and ...

Age-related macular degeneration (AMD), which affects about 200 million people worldwide and can result in legal blindness, impairs an area of the eye (retina) used for reading, driving and many other ...

On completion of the scans and tests, he said: “You have early age-related macular degeneration.” When he saw my face fall, he added: “AMD – it’s very common.” My grandmother suffered.

High and low levels of high-density lipoprotein and a novel single-nucleotide polymorphism were found to be associated with ...

Physical changes are a normal byproduct of aging. Gray hairs and less elastic skin that contributes to wrinkles may be among ...

Lutein plays a pivotal role in safeguarding the eyes by filtering blue light, which can penetrate deep into the eye and ...

Developed by Soliddd Corp, this innovative technology, showcased at CES 2025, represents the “first true vision correction” ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / ...